Hydroxyl-Terminated Polyethylene Glycol Evades Human Pre-existing Anti-polyethylene Glycol Antibodies.
Summary
Analyzing 1,970 human serum samples, the authors show that PEG terminal chemistry dictates binding by pre-existing anti-PEG IgM. Hydroxyl-terminated PEG markedly evades antibody binding and reduces complement activation of lipid nanoparticles, improving stability and reducing mRNA leakage, with lower immunogenicity upon repeated exposure.
Key Findings
- Pre-existing anti-PEG antibodies are prevalent; binding by IgM is strongly influenced by PEG terminal chemistry.
- Hydroxyl-terminated PEG (OH-PEG) significantly evaded binding by anti-PEG IgM across most of 1,970 human samples from three hospitals.
- Replacing MeO-PEG with OH-PEG reduced complement activation of lipid nanoparticles, increased stability, decreased mRNA leakage, and lowered immunogenicity upon repeat exposure.
Clinical Implications
Developers of PEGylated drugs, vaccines, and topical/cosmetic formulations should consider adopting OH-PEG to reduce infusion reactions and hypersensitivity, and incorporate anti-PEG antibody awareness into risk management for repeated dosing.
Why It Matters
This mechanistic human-serum–anchored work provides a directly actionable design rule—use OH-PEG instead of MeO-PEG—to mitigate adverse immune interactions with PEGylated systems across nanomedicine and potentially cosmetics.
Limitations
- Preclinical and ex vivo assays without direct clinical outcome trials.
- Geographic and demographic breadth beyond three hospitals remains to be established; longitudinal dynamics of anti-PEG titers were not assessed.
Future Directions
Prospective clinical studies testing OH-PEG in PEGylated therapeutics and consumer formulations; surveillance of anti-PEG titers; extension to other stealth chemistries and excipients.
Study Information
- Study Type
- Cohort
- Research Domain
- Pathophysiology
- Evidence Level
- III - Observational human-serum analyses with mechanistic laboratory validation
- Study Design
- OTHER